A 52-year-old man with BMI 38 kg/m² presents with morning headaches, daytime somnolence, and witnessed apneas. Arterial blood gas shows pH 7.37, PaCO2 52 mmHg, HCO3 32 mEq/L on room air while awake. Spirometry reveals FVC 65% predicted, FEV1 68% predicted, FEV1/FVC ratio 0.78, and TLC 70% predicted. The spirometric pattern marked **B** in the diagram is consistent with obesity hypoventilation syndrome. Which of the following is the most appropriate first-line management for this patient?
A. Bilevel positive airway pressure (BiPAP) with inspiratory pressure support
B. Theophylline and respiratory stimulant therapy
C. Immediate bariatric surgery referral without trial of PAP therapy
D. Supplemental oxygen therapy alone to maintain SpO2 >90%
Explanation
Why Bilevel positive airway pressure (BiPAP) with inspiratory pressure support is right
The restrictive spirometry pattern marked B — characterized by reduced FVC and FEV1 with preserved FEV1/FVC ratio, reduced TLC and FRC — is the hallmark of obesity hypoventilation syndrome. According to the ATS 2019 Clinical Practice Guideline, positive airway pressure therapy is first-line treatment. BiPAP is specifically indicated for OHS patients with daytime hypercapnia (PaCO2 ≥45 mmHg) and provides inspiratory pressure support that augments tidal volume, directly correcting the hypoventilation that drives the elevated PaCO2. This patient's compensated respiratory acidosis (pH 7.37, HCO3 32) and daytime hypercapnia confirm OHS, making BiPAP the evidence-based initial intervention.
Why each distractor is wrong
Supplemental oxygen therapy alone: Oxygen without ventilatory support can paradoxically worsen hypercapnia by reducing ventilatory drive in patients with chronic CO2 retention and blunted chemoreceptor sensitivity. Oxygen alone does not address the underlying hypoventilation.
Immediate bariatric surgery without PAP trial: While weight loss is the definitive long-term treatment for OHS, bariatric surgery is not first-line. PAP therapy must be optimized first, and surgery is reserved for those who fail medical management or require urgent intervention for severe cor pulmonale.
Theophylline and respiratory stimulants: These agents lack evidence in OHS management and are not recommended by the ATS guideline. They do not provide the mechanical ventilatory support needed to overcome the restrictive mechanics and reduced lung volumes in OHS.
High-YieldNEET PG
OHS = obesity (BMI ≥30) + daytime hypercapnia (PaCO2 ≥45) + sleep-disordered breathing (usually OSA); first-line is PAP (CPAP or BiPAP), NOT oxygen alone; BiPAP preferred for predominant hypoventilation.
ATS Clinical Practice Guideline — Obesity Hypoventilation Syndrome 2019
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
